Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.6K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

1.8K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.8K
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

688
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
688
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

3.1K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
3.1K
Lipid Absorption01:24

Lipid Absorption

3.2K
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
3.2K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

259
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
259

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Design of a water-soluble transmembrane receptor kinase with intact molecular function by QTY code.

Nature communications·2024
Same author

A sustainable carbon aerogel from waste paper with exceptional performance for antibiotics removal from water.

Journal of hazardous materials·2024
Same author

Construction and Verification of Urinary Tract Infection Prediction Model for Hospitalized Rehabilitation Patients with Spinal Cord Injury.

World neurosurgery·2024
Same author

Systematic identification and analysis of immune-related circRNAs of Pelteobagrus fulvidraco involved in Aeromonas veronii infection.

Comparative biochemistry and physiology. Part D, Genomics & proteomics·2024
Same author

Comparative Study of the Short-Term Efficacy and Safety between DEB-TACE and C-TACE in the Treatment of Unresectable Hepatocellular Carcinoma, a Retrospective Study.

Technology in cancer research & treatment·2024
Same author

Inflammatory Markers Associated with Physical Frailty and Cognitive Impairment.

Aging and disease·2024

Related Experiment Video

Updated: Mar 6, 2026

Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

30.8K

Ezetimibe Increases Endogenous Cholesterol Excretion in Humans.

Xiaobo Lin1, Susan B Racette1, Lina Ma1

  • 1From the Division of Endocrinology, Metabolism & Lipid Research, Department of Medicine, Washington University School of Medicine, St. Louis, MO (X.L., S.B.R., L.M., R.E.O.); Program in Physical Therapy, Washington University School of Medicine, St. Louis, MO (S.B.R.); and Division of Biostatistics, Washington University School of Medicine, St. Louis, MO (M.W.).

Arteriosclerosis, Thrombosis, and Vascular Biology
|March 11, 2017
PubMed
Summary

Ezetimibe enhances cholesterol removal from the body by increasing its excretion into stool. This mechanism may explain how ezetimibe improves cardiovascular health when combined with statins.

Keywords:
cholesterolclinical trialezetimibeintestinal eliminationmass spectrometryphysiology

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Related Experiment Videos

Last Updated: Mar 6, 2026

Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

30.8K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Area of Science:

  • Cardiovascular Medicine
  • Metabolic Science
  • Pharmacology

Background:

  • Ezetimibe is known to improve cardiovascular outcomes, particularly when used with statins.
  • While it lowers LDL cholesterol and reduces intestinal cholesterol absorption, its precise cardioprotective mechanism remains unclear.
  • This study investigated whether ezetimibe's primary action is to enhance cholesterol's reverse transport into feces.

Purpose of the Study:

  • To test the hypothesis that ezetimibe's main cardioprotective effect stems from increasing cholesterol excretion into stool.
  • To elucidate the mechanism of ezetimibe's action on whole-body cholesterol metabolism.

Main Methods:

  • A randomized, placebo-controlled, double-blind trial involving 24 healthy subjects.
  • Subjects received either ezetimibe (10 mg/d) or placebo for 6 weeks.
  • Cholesterol metabolism was assessed using stable isotope tracers (cholesterol-d7, cholesterol-d5) and mass spectrometry analysis of plasma and stool samples under a controlled diet.

Main Results:

  • Ezetimibe significantly reduced intestinal cholesterol absorption efficiency by 30% (P<0.0001) and LDL cholesterol by 19.8% (P=0.0001).
  • Fecal endogenous cholesterol excretion increased by 66.6% (P<0.0001), and the percentage of cholesterol excreted from body pools rose by 74.7% (P<0.0001).
  • Plasma cholesterol turnover increased by 26.2% (P=0.0096), while body cholesterol pool size and fecal bile acids remained unchanged.

Conclusions:

  • Ezetimibe enhances the efficiency of reverse cholesterol transport, facilitating the removal of cholesterol from plasma and tissues into the stool.
  • Further research is warranted to connect these findings on cholesterol metabolism to cardiovascular events and atherosclerosis treatment.